Synthesis and anticancer evaluation of imidazolinone and benzoxazole derivatives  by El-Hady, Heba A. & Abubshait, Samar A.
Arabian Journal of Chemistry (2014) xxx, xxx–xxxKing Saud University
Arabian Journal of Chemistry
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLESynthesis and anticancer evaluation
of imidazolinone and benzoxazole derivatives* Corresponding author at: Chemistry Department, Faculty of
Applied Science, Umm al Qura University, PO Box 715, Saudi Arabia.
Tel.: +966 546195348; fax: +966 25580159.
E-mail address: Hebaa_elhady@yahoo.com (H.A. El-Hady).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
1878-5352 ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.arabjc.2014.05.006
Please cite this article in press as: El-Hady, H.A., Abubshait, S.A. Synthesis and anticancer evaluation of imidazolinone and benzoxazol
atives. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.1016/j.arabjc.2014.05.006Heba A. El-Hady a,b,*, Samar A. Abubshait ca Chemistry Department, Faculty of Science (for Girls), Al-Azhar University, Nasr City, Egypt
b Chemistry Department, Faculty of Applied Science, Umm al Qura University, Saudi Arabia




against MCF-7 and HePG2
cell linesAbstract A series of imidazolinone and benzoxazole derivatives (3 and 5) have been synthesized by
the condensation of oxazolinone derivatives (2a–c) with aniline and 2-hydroxyaniline. Acetyl deriv-
atives (4, 6 and 7) were prepared via acetylation of compounds 3 and 5 with acetic anhydride and
chloroacetyl chloride. The results revealed that imidazolinone and benzoxazole derivatives are
potent against the cancer cell lines MCF-7 and HePG2. In particular, benzoxazole derivatives
are more potent than imidazolinone derivatives.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Imidazolinone (Wilson et al., 1998; Behai, 2003) and benzox-
azole derivatives (Isomura et al., 1983; Unidine et al., 2003;
Sham et al., 2006) have been reported to possess anti-inﬂam-
matory, analgesic and kinase inhibition activities in some liter-
ature. The antimicrobial activities of imidazolinones and
benzoxazoles have long been established. Derivatives of these
compounds are known for their antibacterial (Nakamura,
1955), trichomonacidal (Cavaileri et al., 1978), anthelmintic
(Cunkier and Mezey, 1966), fungicidal (Maxwell, 1971) andantiviral (Hollinahead and Smith, 1958) activities. Some of
these compounds exhibited anticancer activity (Shu-Ting
et al., 2006). In a review on the chemistry of imidazolinones
and benzoxazoles, a pit of commercially available compounds
and their therapeutic uses was included. The objective of the
present work was to investigate the anticancer activities of
the synthesized imidazolinone and benzoxazole derivatives.
2. Materials and methods
Melting points were taken in open capillaries with a Thomas
uni-melt apparatus and they are uncorrected. 1H NMR spectra
were recorded on a general electric QE300 instrument and
chemical shifts are given with respect to TMS. The 13C
NMR (500 MHz) spectra were run in dimethyl sulfoxide
(DMSO-d6). Chemical shifts were related to that of the solvent.
IR spectra were recorded on a Perkin-Elmer 1420 spectrometer
and a Bio-Rad FTS7 (KBr). Mass spectra were obtained on a
Joel JMS D-300 spectrometer operating at 70 Ev. Microanaly-
ses were conducted using an elemental analyzer 1106.e deriv-
2 H.A. El-Hady, S.A. Abubshait(Z)-4-(arylidene)-2-aryloxazol-5(4H)-ones (2a–c). A mix-
ture of N-aroylglycine (0.01 mol), aromatic aldehydes (such
as 4 hydroxybenzaldehyde and 3-bromo-4-hydroxybenzalde-
hyde) (0.01 mol) and fused sodium acetate (0.03 mol) was
fused in the presence of acetic anhydride (5 ml) on a hot plate
for 3–5 min. The reaction mixture was heated on a water-bath
for 2 h, then cooled and poured into water. The resulting solid
was ﬁltered off, washed with water, dried and puriﬁed by suit-
able solvent to give 2.
(Z)-4-(4-hydroxybenzylidene)-2-phenyloxazol-5(4H)-one
(2a) as yellow crystals, yield 63%, m.p. 165 C. IR (KBr):
3430–2895 (br. OH), 1758 (C‚O), 1628 (C‚N), 1615, 1589
(C‚C), 1215, 1178, 1095 (CAO) cm1. 1H NMR (DMSO-
d6) d: 7.12–7.81 (m, 10H, Ar-H and H-oleﬁnic), 11.23 (s, 1H,
OH) ppm. Anal. Calcd. For C16H11NO3: C, 72.45; H, 4.15;
N, 5.28. Found: C, 72.22; H. 4.03; N, 5.17.
(Z)-4-(3-bromo-4-hydroxybenzylidene)-2-phenyloxazol-
5(4H)-one (2b) as yellow crystals, yield 71%, m.p.187 C. IR
(KBr): 3421–2981 (br. OH). 1751 (C‚O), 1629 (C‚N),
1612, 1592 (C‚C), 1178, 1085 (CAO) cm1. 1H NMR
(DMSO-d6): d: 7.12–7.81(m, 9H, Ar-H and H-oleﬁnic), 11.3
(s, 1H, OH) ppm. Anal. Calcd. For C16H10NBrO3: C, 55.98;
H, 2.91; N, 4.08. Found: C, 55.68; H, 2.71; N, 3.98.
(Z)-4-(3-bromo-4-hydroxybenzylidene)-2-(4-chlorophenyl)-
oxazol-5(4H)-one (2c) as yellow crystals, yield 73%, m.p.
186 C. IR (KBr): 3395–2820 (br. OH), 1756 (C‚O), 1627
(C‚N), 1613, 1583 (C‚C), 1215, 1125, 1095 (CAO) cm1.
1H NMR (DMSO-d6) d: 7.12–7.88 (m, 8H, Ar-H and H-ole-
ﬁnic), 1 1.37 (s, 1H, OH) ppm. Anal. Calcd. For C16H9NCl-





vinyl)benzamide (5a, b). A mixture of 2 (0.01 mol) and aro-
matic amines (namely, aniline and 2-hydroxy aniline) in acetic
acid (30 ml) was heated under reﬂux for 4 h. The reaction mix-
ture was cooled and poured into ice-water. The solid obtained
was ﬁltered off, washed with water, dried and puriﬁed by suit-
able solvent to give 3 and 5.
4-(3-bromo-4-hydroxybenzylidene)-1, 2-diphenyl-1H-imida-
zol-5(4H)-one (3a) as yellow crystals, yield 67%, m.p.
212 C. IR (KBr): 3381–2851 (br. OH), 1695 (C‚O), 1628
(C‚N), 1616, 1595 (C‚C), 1175, 1043 (CAO) cm1. 1H
NMR (DMSO-d6) d: 6.98–7.83 (m, 14H, Ar-H and H-oleﬁnic),
11.21 (s, 1H, OH) ppm. 13C NMR (DMSO-d6) d: 173.2(C‚O),
150 (N‚CAN), 131.9, 134.1 (HC‚C), 110.0, 118.2, 121.9,
124.1, 125.4, 126.2, 128.2, 128.3, 129.4, 129.9, 130.5, 132.6,
138.0, 159.6 (Caromatic). MS: m/z (%) = 420 (M
+2, 5.30), 418
(M+, 5.60), 181 (3.90), 480 (17.80), 179 (6.10), 125 (2.80),
119 (5.60), 118 (3.30), 114 (3.30), 106 (14.40), 105 (100), 104
(23.90), 103 (4.40), 101 (5.00), 94 (4.40), 93 (24.40), 92
(27.80), 88 (3.90), 87 (4.40), 81 (6.70), 80 (5.60), 79 (4.40), 77
(55.00), 76 (48.30), 75 (7.80), 66 (11.10), 65 (12.20), 64 (6.70),
51 (20.00), 50 (15.60), Anal. Calcd. For C22H15N2BrO2: C,
63.16; H, 3.59; N, 6.69. Found: C, 63.01; H, 3.37; N, 6.51.
4-(3-bromo-4-hydroxybenzylidene)-2-(4-chlorophenyl)-1H-
1-phenyl-imidazol-5(4H)-one (3b) as yellow crystals, yield
73%, m.p. 217 C. IR (KBr): 3392–2912 (br. OH), 1699
(C‚O), 1625 (C‚N), 1613, 1581 (C‚C), 1185, 1078 (CAO)
cm1. 1H NMR (DMSO-d6) d: 6.89–7.81 (m, 13H, Ar-H and
H-oleﬁnic), 11.31 (s, 1H, OH) ppm. 13C NMR (DMSO-d6) d:Please cite this article in press as: El-Hady, H.A., Abubshait, S.A. Synthes
atives. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.1016/j.a173.0 (C‚O), 150.6 (N‚C-N), 131.6, 133.9 (HC‚C), 109.8,
117.6, 120.1, 124.0, 126.2, 126.8, 128.1, 129.0, 129.2, 130.7,
132.0, 134.7, 137.9, 159.5 (Caromatic). MS: m/z (%) = 456
(M+4, 2.40), 454 (M+2, 4.30), 452 (M+, 3.70), 266 (1.80),
217 (2.40), 216 (13.70), 215 (7.60), 214 (34.80), 213 (25.00),
209 (2.70), 186 (1.50), 185 (2.70), 180 (4.60), 179 (3.40), 178
(3.40), 169 (3.70), 168 (4.30), 156 (3.00), 154 (3.00), 151
(2.70), 142 (4.00), 141 (34.50), 140 (24.40), 139 (100), 138
(69.80), 113 (8.50), 112 (6.40), 111 (23.50), 110 (20.10), 105
(14.30), 104 (10.70), 103 (4.60), 102 (5.80), 101 (6.70), 94
(7.00), 93 (42.70), 92 (27.10), 91 (3.70), 87 (6.70), 82 (4.30),
81 (3.00), 80 (1.50), 78 (9.50), 77 (95.70), 76 (38.70), 75
(19.50), 66 (6.10), 65 (7.30), 64 (5.20), 51 (47.00), 50 (21.60),
Anal. Calcd. For C22H14N2ClBrO2: C, 58.41; H, 3.10; N,
6.19. Found: C, 58.17; H, 2.93; N, 6.01.
(Z) 2-[b- (4-Hydroxyphenyl)-a-(benzoylamino) vinyl]-
benzoxazole (5a) as yellow crystals, yield 64%, m.p. 135 C.
IR (KBr): 3225 (NH), 3351–2815 (br. OH), 1689 (CO), 1628
(C‚N), 1615, 1589 (C‚C), 1195, 1081 (C-O) cm1. 1H
NMR (DMSO-d6) d: 6.93–7.89 (m, 14H, Ar-H and H-oleﬁnic),
9.83 (br. s, 1H, NH), 11.23 (s, 1H, OH) ppm. MS: m/z
(%) = 357 (M+2, 7.10), 356 (M+, 26.40), 355 (M1, 16.00),
328 (1.20), 327 (1.70), 265 (2.60), 264 (1.50), 263 (1.60),
253 (1.70), 251 (3.30), 250 (2.10), 236 (1.50), 235 (2.40), 224
(1.80), 197 (6.00), 196 (22.60), 195 (12.00), 180 (1.20), 178
(2.90), 167 (3.30), 166 (3.20), 145 (1.60), 141 (1.20),
133 (1.60), 132 (6.00), 131 (2.70), 121 (1.80), 120 (1.50), 119
(2.40), 118 (3.40), 117 (2.00), 106 (10.00), 105 (100),
104 (84.90), 103 (12.20), 93 (3.90), 92 (2.90), 91 (2.20), 89
(4.40), 88 (2.80), 78 (5.40), 77 (36.60), 76 (27.00), 75 (4.20),
65 (17.60), 64 (16.60), 63 (8.10), 51 (13.20), 50 (7.60) .Anal.
Calcd. For C22H16N2O3: C, 74.16; H, 4.49; N, 7.86. Found:
C, 74.03; H, 4.23; N, 7.61.
(Z) 2-[b-(3-bromo-4-Hydroxyphenyl)-a-(benzoyl amino)
vinyl]-benzoxazole (5b) as orange crystals, yield 67%, m.p.
125 C, IR (KBr): 3395–2950 (br. OH), 3223 (NH), 1687
(C‚O), 1628 (C‚N), 1612, 1588 (C‚C), 1215, 1089 (CAO)
cm1. 1H NMR (DMSO-d6) d: 6.98–7.87 (m, 13H, Ar-H and
H-oleﬁnic), 9.81 (s, 1H, NH), 11.26 (s, IH, OH) ppm. 13C
NMR (DMSO-d6) d: 164.0 (C‚O), 152.1 (N‚CAOA),
132.6, 105.3 (HC‚C), 11O.2, 117.3, 120.2, 124.0, 124.9,
126.4, 126.9, 128.2, 129.5, 130.6, 131.6, 133.2, 140.0, 149.0,
159.4, 163.9 (Caromatic) MS: m/z (%) = 436 (M
+2, 1.30), 434
(M+,1.60), 423 (7.40), 421 (10.60), 417 (7.40), 377 (6.40), 280
(6.40), 279 (0.60), 278 (7.40), 265 (8.50), 264 (6.40), 197
(4.30), 196 (12.80), 195 (45.70), 194 (19.10), 180 (16.00),
179 (12.80), 168 (4.30), 167 (21.30), 166 (11.70), 156 (6.40),
155 (8.50), 151 (9.60), 150 (10.60), 149 (22.30), 148 (14.90),
141 (18.10), 139 (23.40), 138 (22.30), 133 (18.10), 132 (12.80),
122 (7.40), 121 (12.80), 120 (19.10), 119 (19.10), 112 (11.70),
111 (13.80), 110 (10.80), 109 (19.10), 106 (14.90), 105 (100),
104 (83.00), 93 (18.10), 92 (19.10), 91 (17.00), 85 (10.60), 84
(12.80), 82 (10.50), 80 (13.80), 79 (7.40), 78 (20.20), 77
(55.30), 76 (47.90), 75 (22.30), 73 (11.70), 71 (16.00), 70
(12.80), 66 (12.80), 65 (18.10), 64 (30.90), 63 (29.80), 62
(25.50), 60 (20.20), 51 (38.30), 50 (21.30), Anal. Calcd. For C22-
H15N2BrO3: C, 60.83; H, 3.45; N, 6.45. Found: C, 60.61; H,
3.22; N, 6.31.
(E)-2-bromo-4-[(2-(4-chlorophenyl)-5-oxo-1-phenyl-1H-
imidazol-4(5-ylidene) methyl] phenyl acetate (4a, b).
(Z)-4-(2-benzamido-2-(benzo[d]oxazol-2-yl) vinyl)-2-
bromophenyl acetate (6). A solution of 3 and 5b (0.01 mol) inis and anticancer evaluation of imidazolinone and benzoxazole deriv-
rabjc.2014.05.006
Synthesis and evaluation of imidazolinone 3acetic anhydride (20 ml) was heated under reﬂux for 2hr, then
cooled and poured into ice-water. The solid formed was ﬁl-
tered off, washed with water, dried and puriﬁed by recrystalli-
zation from benzene to give 4 and 6.
(E)-2-bromo-4-[(5-oxo-1, 2-diphenyl-1H-imidazol-4(5H)-
ylidene) methyl] phenyl acetate (4a) as yellow crystals, yield
63%, m.p.110 C. IR (KBr): 1748, 1693 (C‚O), 1625
(C‚N), 1605, 1598 (C‚C), 1215, 1093 (CAO) cm1. 1H
NMR (DMSO-d6) d: 2.33 (s, 3H, COCH3), 6.98–7.81 (m,
14H, Ar-H and H-oleﬁnic) ppm. 13C NMR (DMSO-d6) d:
172.9, 167.5 (2C‚O), 149.9 (N‚CAN), 132.0, 134.1
(HC‚C), 16.2 (CH3aliph.), 114.9, 120.0, 122.9, 123.9, 125.0,
125.3, 128.3, 128.4, 129.6, 132.5, 133.4, 128.4, 129.6, 132.5,
133.4, 137.9, 155.2 (Caromatic). MS: m/z (%) = 462 (M
+2,
0.20), 460 (M+, 0.30), 425 (72.4), 424 (74.20), 423 (84.70),
422 (94.50), 420 (13.20), 345 (43.60), 344 (41.20), 343 (41.50),
291 (1.03), 290 (1.30), 289 (0.30), 181 (6.30), 180 (8.30), 171
(7.80), 149 (0.30), 148 (0.40), 141 (0.30), 139 (4.20),
136 (3.60), 135 (0.70), 134 (0.30), 106 (9.10), 105 (100), 103
(1.20), 102 (0.70), 101 (1.20), 100 (1.70), 88 (0.60), 87 (1.60),
78 (3.70), 77 (50.90), 75 (2.70), 65 (0.50), 64 (0.40), 63 (1.10),
62 (1.30), 52 (1.20), 51 (17.10), 50.20 (9.00) Anal. Calcd. For
C24H17N2BrO3: C, 62.61; H, 3.69; N, 6.09. Found: C, 62.43;
H, 3.39; N, 5.97.
(E)-2-bromo-4-[(2-(4-chlorophenyl)-5-oxo-1-phenyl-1H-
imidazol-4(5H)-ylidene)methyl]phenyl acetate (4b) as yellow
crystals, yield 66%, m.p. 100 C. IR (KBr): 1746, 1693
(C‚O), 1623 (C‚N), 1607, 1588 (C‚C), 1195, 1093 (CAO)
cm1. 1H NMR (DMSO-d6) d: 2.34 (s, 3H, COCH3), 6.89–
7.83 (m, 13H, Ar-H and H-oleﬁnic) ppm. 13C NMR
(DMSO-d6) d: 173.4, 167.2 (2C‚O), 149.4 (N‚CAN),
133.9, 132.0 (HC‚C), 16.5 (Caliph.), 115.2, 119.6, 122.4,
123.1, 126.8, 128.7, 129.0, 129.7, 130.9, 133.3, 134.5, 138.0,
155.6. MS: m/z (%) = 496 (M+2, 2.30), 494 (M+, 3.30), 459
(4.10), 458 (4.10), 457 (7.60), 456 (7.40), 455 (3.30),
454 (3.60), 423 (2.80), 215 (1.80), 214 (5.60), 180 (3.80), 169
(1.30), 168 (4.80), 167 (2.30), 152 (1.50), 142 (2.80),
141 (29.30), 140 (23.20), 139 (100), 138 (84.00), 118 (2.30),
113 (7.60), 112 (6.40), 111 (25.40), 110 (27.50), 106 (4.10),
105 (23.40), 104 (30.00), 103 (4.10), 102 (1.20), 100 (3.80), 93
(7.10), 92 (10.40), 91 (2.00), 88 (2.50), 87 (3.30), 81 (2.80), 77
(26.50), 76 (15.30), 75 (21.10), 74 (12.50), 63 (3.30), 62 (2.50),
61 (2.30), 60 (3.80), 51 (9.90), 50 (10.70).Anal. Calcd. For C24-
H16N2BrClO3: C, 58.24; H, 3.23; N, 5.66. Found: C, 58.03; H,
3.17; N, 5.42.
Compound 6 as yellow crystals, yield 53%, m.p. 105 C. IR
(KBr): 1742, 1685 (C‚O), 3228 (NH), 1631 (C‚N), 1610,
1605, 1589 (C‚C), 1223, 1178, 1075 (CAO) cm1. 1H NMR
(DMSO-d6) d: 2.35 (s, 3H, OCOCH3), 6.89–7.88 (m, 13H,
Ar-H and H-oleﬁnic), 9.83 (br. s, 1H, NH) ppm. 13C NMR
(DMSO-d6) d: 164.0, 167.0 (2C‚O), 152.2 (N‚CAOA),
132.4, 105.0 (HC‚C), 16.6 (CH3aliph.), 110.1, 115.7, 120.0,
123.5, 123.9, 124.9, 125.2, 127.1, 128.4, 128.5, 131.2, 133.1,
133.5, 140.0, 150.0, 155.4 (Caromatic). MS: m/z (%) = 478
(M+2, 1.30), 477 (M+, 1.60), 459 (3.00), 458 (5.10), 457
(3.60), 456 (3.00), 425 (3.30), 429 (5.40), 423 (5.70), 422
(1.50), 361 (1.50), 347 (1.80), 346 (1.80), 345 (1.80), 264
(2.40), 263 (1.50), 183 (1.50), 180 (2.10), 167 (1.20),
158 (1.80), 157 (1.80), 152 (1.50), 140 (10.00), 139 (37.20),
138 (30.50), 133 (3.30), 132 (2.10), 118 (3.00), 117 (1.50), 113
(5.10), 112 (4.20), 111 (12.10), 110 (8.80), 109 (10.30), 108
(9.40), 106 (11.80), 105 (100), 104 (87.90), 103 (3.30), 93Please cite this article in press as: El-Hady, H.A., Abubshait, S.A. Synthes
atives. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.1016/j.a(9.40), 92 (6.30), 87 (3.90), 85 (4.20), 79 (4.80), 78 (6.60), 77
(44.40), 76 (24.80), 75 (8.50), 65 (6.90), 62 (3.30), 60 (10.90),
51 (14.50), 50 (10.00). Anal. Calcd. For C24H17N2BrO4: C,
60.50; H, 3.57; N, 5.88. Found: C, 60.33; H, 3.33; N, 5.66.
(Z)-4-(2-benzamido-2-(benzo[d]oxazol-2-yl) vinyl)-2-
bromophenyl 2-chloroacetate (7).
A mixture of 5b (0.01 mol) and chloroacetyl chloride
(0.01 mol) in acetic acid (25 ml) was heated under reﬂux for
2 h, then cooled and poured into ice-water. The resulting solid
was ﬁltered off, washed with water, dried and puriﬁed by
recrystallization from benzene to give 7 as yellow crystals, yield
67%, m.p. 118 C. IR (KBr): 3230 (NH), 1748, 1687 (CO),
1626 (C‚N), 1610, 1587 (C‚C), 1195, 1078 (CAO) cm1.
1H NMR (DMSO-d6) d: 4.35 (s, 2H, COCH2Cl), 6.89–7.89
(m, 13H, Ar-H and H-oleﬁnic), 9.83 (s, 1H, NH) ppm. 13C
NMR (DMSO-d6) d: 164.2, 163.1 (2C‚O), 152.5
(N‚CAOA), 132.6, 104.8 (HC‚C), 47.5 (ACH2ACl),
110.3, 115.9, 120.1, 122.9, 123.8, 125.0, 125.2, 126.8, 127.9,
129.7, 131.3, 133.2, 133.5, 139.8, 150.0, 155.2 (Caromatic). MS:
m/z (%) = 512 (M+2, 1.30), 510 (M+, 1.50), 500 (11.10),
498 (14.80), 497 (18.50), 496 (14.80), 280 (11.10), 279 (9.30),
278 (7.40), 180 (38.90), 179 (50.00), 159 (24.10), 141 (9.30),
127 (9.30), 106 (7.40), 105 (94.40), 104 (100), 99 (13.00), 98
(13.00), 94 (7.40), 91 (18.50), 78 (16.70), 77 (66.70), 76
(66.70), 75 (14.80), 74 (16.70), 68 (11.10), 67 (11.10), 61
(13.00), 60 (27.80), 58 (20.40), 51 (35.20), 50 (35.20). Anal.
Calcd. For C24H16N2BrClO4: C, 56.47; H, 3.14; N, 5.49;
Found: C, 56.27; H, 3.03; N, 5.23.
3. Results and discussion
3.1. Chemistry
(Z)-4-Arylidene-2-aryloxazol-5(4H)-one (2a–c) have been
synthesized by the condensation of N-aroylglycine (1a, b) with
3-substituted-4-hydroxy benzaldehyde in the presence of fused
sodium acetate and acetic anhydride under fusion (Kaushik
et al., 2010). 4-(3-Bromo-4-hydroxybenzylidene)-2-aryl-1H-1-
phenyl-imidazol-5(4H)-ones(3a, b) were prepared by the reac-
tion of compounds (2b,c) with aniline by reﬂuxing in acetic
acid. Acetylation of 4-(3-bromo-4-hydroxybenzylidene)-
2-aryl-1H-1-phenyl-imidazol-5(4H)-ones (3a, b) with acetic
anhydride yielded the corresponding (E)-2-bromo-4-
[(2-(4-chlorophenyl)-5-oxo-1-phenyl-1H-imidazol-4(5-ylidene)-
methyl] phenyl acetate (4a, b; Scheme 1). Treatment of
oxazolinone derivatives (2a, b) with 2-aminophenol by
reﬂuxing in acetic acid afforded the corresponding (Z)-N-(1-
(benzo[d]oxazol-2-yl)-2-(4-hydroxyphenyl) vinyl) benzamide
(5a, b; Scheme 1). Acetylation of (Z)2-[b-(3-bromo-4-Hydroxy-
phenyl)-a-(benzoylamino)vinyl]-benzoxazole (5b) with acetic
anhydride and chloroacetyl chloride gave the corresponding
(Z)-4-(2-benzamido-2-(benzo[d]oxazol-2-yl)vinyl)-2-bromophe-
nyl acetate 6 and (Z)-4-(2-benzamido-2-(benzo[d]oxazol-2-
yl)vinyl)-2-bromophenyl 2-chloroacetate 7, respectively.
3.2. Cytotoxicity assays
Imidazolinone and benzoxazole derivatives were evaluated for
their human tumor cell growth inhibitory activity against two
cell lines: MCF-7 (breast carcinoma) and HePG2 (hepatocellu-
lar carcinoma). The measurements of cell growth and viabilityis and anticancer evaluation of imidazolinone and benzoxazole deriv-
rabjc.2014.05.006






a, R= H; Ar= C6H5
b, R= Br; Ar= C6H5
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a, Ar= C6H5; b, Ar= C6H4-Cl-p
a, Ar= C6H5; b, Ar= C6H4-Cl-p
O
Scheme 1 Preparation of oxazolone (2a–c), imidazolone (3a, b, 4a, b) and benzoxazolone derivatives (5a, b, 6, 7).
4 H.A. El-Hady, S.A. Abubshaitwere determined as described in the Mossman (1983) and Vija-
yan et al. (2004) method (Mosmann, 1983; Vijayan et al.,
2004). Inhibitory activity against breast carcinoma cells
(MCF-7 cell line) and hepatocellular carcinoma cells (HePG2
cell line) was tested by using different concentrations of the
imidazolinones, benzoxazoles and vinblastine drug as standard
reference. The viability cells (%) were determined by the color-
imetric method. Inhibitory concentration ﬁfty (IC50) of pre-
pared compounds of MCF-7 cell line were calculated from
Table 1 and Figs. 1 and 2.Table 1 Evaluation of cytotoxicity of imidazolinones and benzoxa
Sample conc. (lg) Viability%
Imidazolinones
3a 3b 4b
50 34.84 25.28 24.16
25 48.96 39.74 40.48
12.50 67.39 57.96 57.12
6.25 80.94 73.18 79.87
3.125 91.12 89.22 90.54
1.56 97.98 96.15 97.31
0 100 100 100
Please cite this article in press as: El-Hady, H.A., Abubshait, S.A. Synthes
atives. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.1016/j.aInhibitory concentration ﬁfty (IC50) of synthesized com-
pounds of HePG2 cell line were calculated from Table 2 and
Figs. 3 and 4.
The results of inhibitory concentration ﬁfty (IC50) data are
summarized in Table 3.
IC50: is the concentration that induces 50% growth inhibi-
tion compared with untreated cells.
MCF-7 = human breast carcinoma cell line.
HePG2 = human hepatocellular carcinoma cell line.zoles against MCF-7 cell line.
Benzoxazoles
5a 5b 6 Vinblastine standard
19.58 21.74 26.47 7.82
35.24 38.33 39.74 15.18
48.32 54.85 59.96 29.60
69.26 72.47 73.18 48.75
84.51 88.19 89.22 60.35
93.24 96.54 95.46 76.24
100 100 100 100
is and anticancer evaluation of imidazolinone and benzoxazole deriv-
rabjc.2014.05.006















Figure 1 Evaluation of cytotoxicity of compounds (3a, 3b, 4b, and standard vinblastine) against MCF-7 cell line.















Figure 2 Evaluation of cytotoxicity of compounds (5a, 5b, 6, and standard vinblastine) against MCF-7 cell line.
Table 2 Evaluation of cytotoxicity of imidazolinones and benzoxazoles of HePG2 cell line.
Sample conc. (lg) Viability%
Imidazolinones Benzoxazoles
3a 3b 4b 5a 5b 6 Vinblastine standard
50 18.63 14.59 19.66 13.80 15.07 15.86 14.38
25 27.56 23.75 28.26 24.74 22.42 26.37 16.13
12.50 58.12 40.62 49.32 33.32 51.08 37.84 24.25
6.25 72.29 76.88 75.56 51.16 74.86 51.58 45.13
3.125 81.41 89.55 88.84 65.14 90.52 68.61 55.00
1.56 90.93 97.63 93.77 81.71 98.34 82.15 72.13
0 100 100 100 100 100 100 100
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Figure 3 Evaluation of cytotoxicity of compounds (3a, 3b, 4b, and standard vinblastine) against HePG2 cell line.
















Figure 4 Evaluation of cytotoxicity of compounds (5a, 5b, 6, and standard vinblastine) against HePG2 cell line.
Table 3 IC50 (lg) values of tumor cell lines after 72 h
continuous exposure to test.








Vinblastine standard 6.10 4.60
6 H.A. El-Hady, S.A. AbubshaitIn comparison with standard antitumor vinblastine, com-
pound 5a is found to be less IC50 value (12.0 lg) than other
tested compounds against the human breast tumor cellsPlease cite this article in press as: El-Hady, H.A., Abubshait, S.A. Synthes
atives. Arabian Journal of Chemistry (2014), http://dx.doi.org/10.1016/j.a(MCF-7). Compounds 5a and 6 are also found to be less
IC50 values (6.79 and 6.90 lg) than other tested compounds
against the human hepatocellular carcinoma cells (HePG2).
Benzoxazole derivatives are found to exhibit stronger antican-
cer activity cell lines than those of imidazolinone derivatives
from the inhibitory concentration ﬁfty (IC50) results.
4. Conclusion
The biological results obtained for compounds 3–6 described
in this paper conﬁrm that they are most potent against the
human breast tumor cells (MCF-7) and human hepatocellular
cancer cells (HePG2). Compounds 5a and 6 have the most
prominent activity against the human hepatocellular tumor
cells (HePG2) IC50 = (6.7 lg/ml) to (6.9 lg/ml).is and anticancer evaluation of imidazolinone and benzoxazole deriv-
rabjc.2014.05.006
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